Article
Clinical Neurology
Christina Rabe, Tobias Bittner, Alexander Jethwa, Ivonne Suridjan, Ekaterina Manuilova, Michel Friesenhahn, Erik Stomrud, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Summary: This study evaluated the clinical performance and robustness of plasma Aβ(42)/Aβ(40) as a prescreening tool for Alzheimer's disease. It found that there were misclassifications caused by measurement errors and pre-analytical errors, and suggested that other blood biomarkers may be easier to implement as robust prescreening tools.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Feifei Ge, Lin Dong, Donglin Zhu, Xingjian Lin, Jingping Shi, Ming Xiao
Summary: Thyroid dysfunction has been implicated in the pathogenesis of Alzheimer's disease (AD). This study found that even in euthyroid subjects, low levels of serum FT3 and TT3 are differentially associated with AD-specific CSF changes. Serum FT3 is a strong candidate for the differential diagnosis between AD continuum and non-AD dementia, benefiting the early diagnosis and effective management of AD patients.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Clinical Neurology
Clifford R. Jack Jr, Heather J. Wiste, Alicia Algeciras-Schimnich, Dan J. Figdore, Christopher G. Schwarz, Val J. Lowe, Vijay K. Ramanan, Prashanthi Vemuri, Michelle M. Mielke, David S. Knopman, Jonathan Graff-Radford, Bradley F. Boeve, Kejal Kantarci, Petrice M. Cogswell, Matthew L. Senjem, Jeffrey L. Gunter, Terry M. Therneau, Ronald C. Petersen
Summary: Staging the severity of Alzheimer's disease pathology is important for therapeutic trials and clinical prognosis. Biomarkers such as amyloid and tau PET can be used for disease staging, but plasma biomarkers would be more practical.
Article
Clinical Neurology
Shuntaro Natsume, Hajime Baba, Hitoshi Maeshima, Takao Saida, Naoto Yoshinari, Kentaro Shimizu, Toshihito Suzuki
Summary: Depression is a risk factor for Alzheimer's disease, and changes in A13 protein metabolism may contribute to the transition from depression to AD. This study found that elderly patients with depression had decreased A1342 levels at admission, but these levels recovered to healthy levels 1 year after remission.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Neurosciences
Mari Aksnes, Hans Christian D. Aass, Ann Tiiman, Lars Terenius, Nenad Bogdanovi, Vladana Vukojevi, Anne-Brita Knapskog
Summary: In this small pilot study, there was no association between serum nanoplaques and serum cytokines in patients assessed at a memory clinic. This suggests that serum nanoplaque levels cannot be used to differentiate clinical AD patients from non-AD patients in this unselected memory clinic cohort.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Santiago Ramirez, Suelyn Koerich, Natalia Astudillo, Nicole De Gregorio, Rabab Al-Lahham, Tyler Allison, Natalia Pessoa Rocha, Fei Wang, Claudio Soto
Summary: This study aimed to evaluate the effect of removing Aβ from blood plasma on the accumulation of amyloid plaques in the brain. The results showed a reduction in Aβ levels in the plasma and insoluble brain fractions, as well as a decrease in amyloid plaque burden and changes in plaque size distribution in the cortex and hippocampus. These findings support the importance of targeting Aβ in the periphery and suggest plasma exchange as a potential non-pharmacological strategy for slowing down AD pathogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Lei Liu, Bianca M. Lauro, Amy He, Hyo Lee, Sanjay Bhattarai, Michael S. Wolfe, David A. Bennett, Celeste M. Karch, Tracy Young-Pearse, Dennis J. Selkoe
Summary: This study aims to identify biomarkers for Alzheimer's disease (AD) and finds that the A beta 37/42 ratio can be used to distinguish AD from normal aging. Experimental results show that this ratio outperforms the traditional ratio in differentiating physiological and pathological states in cell culture, brain tissue, and cerebrospinal fluid. The findings may provide a new indicator for early diagnosis of AD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Ling-Zhi Ma, Hao Hu, Zuo-Teng Wang, Ya-Nan Ou, Qiang Dong, Lan Tan, Jin-Tai Yu
Summary: The study found that early accumulation of A beta protein in Alzheimer's disease has an independent effect on cognitive decline in normal controls, but has a tau and neurodegeneration-dependent effect on subsequent cognitive decline in patients with mild cognitive impairment.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Article
Clinical Neurology
Lei Liu, Hyunchang Kwak, Trebor L. Lawton, Shan-Xue Jin, Angela L. Meunier, Yifan Dang, Beth Ostaszewski, Alison C. Pietras, Andrew M. Stern, Dennis J. Selkoe
Summary: The study developed a new method for detecting and quantifying soluble oligomers of amyloid beta protein in human plasma. The method is highly sensitive, cost-effective, and suitable for high throughput analysis.
ALZHEIMERS & DEMENTIA
(2022)
Editorial Material
Neurosciences
Allyson C. Rosen, Jalayne J. Arias, J. Wesson Ashford, Deborah Blacker, Jasmeer P. Chhatwal, Nathan A. Chin, Lindsay Clark, Sharon S. Denny, Jill S. Goldman, Carey E. Gleason, Joshua D. Grill, Judith L. Heidebrink, Victor W. Henderson, James A. Lavacot, Jennifer H. Lingler, Malavika Menon, Rachel L. Nosheny, Fabricio F. Oliveira, Monica W. Parker, Annalise Rahman-Filipiak, Anwita Revoori, Malia C. Rumbaugh, Danurys L. Sanchez, Suzanne E. Schindler, Christopher G. Schwarz, Leslie Toy, Jamie Tyrone, Sarah Walter, Li-San Wang, Ellen M. Wijsman, Doris T. Zallen, Neelum T. Aggarwala
Summary: The public is increasingly recognizing the value of accessing dementia risk evidence (DRE) as it can guide diagnosis and clinical management, while researchers are considering how to share and use this evidence.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Clinical Neurology
Stephen Zicha, Randall J. Bateman, Leslie M. Shaw, Henrik Zetterberg, Anthony W. Bannon, Wesley A. Horton, Mike Baratta, Hartmuth C. Kolb, Iwona Dobler, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Emmanouil (Manos) Spanakis, Yan Li, Suzanne E. Schindler, Kyle Ferber, Carrie E. Rubel, Robert L. Martone, Christopher J. Weber, Rebecca M. Edelmayer, Emily A. Meyers, James G. Bollinger, Erin G. Rosenbaugh, William Z. Potter
Summary: This study evaluated the performance of six plasma A beta assays in predicting amyloid positivity compared to age and APOE genotype. The results showed that three of the assays significantly improved the prediction accuracy, and plasma A beta 42/40 predicted amyloid PET status better than A beta 42 or A beta 40 alone.
ALZHEIMERS & DEMENTIA
(2023)
Article
Geriatrics & Gerontology
Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Jodi D. Edwards, Joel Ramirez, Mario Masellis, Richard H. Swartz, Nathan Herrmann, Krista L. Lanctot, Sandra E. Black, Walter Swardfager
Summary: This study suggests that ARBs may be more effective than ACE-Is in protecting against memory decline by slowing amyloid-beta accumulation in certain brain regions. Differences in amyloid-beta accumulation rates between ARB and ACE-I users may be influenced by apolipoprotein E epsilon 4 carrier status. Further studies and clinical trials are needed to confirm the potential benefits of ARBs in Alzheimer's disease prevention and treatment.
NEUROBIOLOGY OF AGING
(2021)
Article
Biochemistry & Molecular Biology
Ekaterina A. Litus, Alexey S. Kazakov, Evgenia I. Deryusheva, Ekaterina L. Nemashkalova, Marina P. Shevelyova, Aliya A. Nazipova, Maria E. Permyakova, Elena V. Raznikova, Vladimir N. Uversky, Sergei E. Permyakov
Summary: The study found that serotonin (SRO) can increase the affinity between A beta monomer and human serum albumin (HSA), while tryptophan (TRP) has a lesser effect on HSA affinity. Serotonin binding results in structural changes in HSA, which may lead to the inability of HSA to effectively trap A beta during AD pathogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Nuria Guillen, Jose Contador, Mariateresa Buongiorno, Ignacio Alvarez, Natalia Culell, Daniel Alcolea, Alberto Lleo, Juan Fortea, Gerard Pinol-Ripoll, Anna Carnes-Vendrell, Maria Lourdes Ispierto, Dolores Vilas, Albert Puig-Pijoan, Aida Fernandez-Lebrero, Mircea Balasa, Raquel Sanchez-Valle, Albert Llado
Summary: This study analyzed the agreement between AD CSF biomarkers and amyloid-PET, and found that there was incomplete agreement between single CSF biomarkers and amyloid-PET. However, biomarker ratios and combined biomarkers improved the agreement.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2023)
Article
Neurosciences
Justin Miron, Cynthia Picard, Anne Labonte, Daniel Auld, Judes Poirier
Summary: This study analyzed the interaction between MSR1 and NEP with AD-related markers (CSF A beta(1-42), ApoE, ApoJ) and confirmed this relationship in autopsied brain samples from ROSMAP.
JOURNAL OF ALZHEIMERS DISEASE
(2022)